In severe chronic rhinosinusitis with polyps and asthma, dupilumab improved nasal polyp score and sense of smell vs. omalizumab at 24 wk

Ann Intern Med. 2026 Feb;179(2):JC20. doi: 10.7326/ANNALS-25-05457-JC. Epub 2026 Feb 3.

Abstract

GIM/FP/GP: [Formula: see text] Allerg & Immunol: [Formula: see text] Pulmonology: [Formula: see text].

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Anti-Asthmatic Agents* / therapeutic use
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Asthma* / complications
  • Asthma* / drug therapy
  • Chronic Disease
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nasal Polyps* / complications
  • Nasal Polyps* / drug therapy
  • Omalizumab* / therapeutic use
  • Rhinitis* / complications
  • Rhinitis* / drug therapy
  • Rhinosinusitis
  • Severity of Illness Index
  • Sinusitis* / complications
  • Sinusitis* / drug therapy
  • Smell / drug effects

Substances

  • Omalizumab
  • dupilumab
  • Antibodies, Monoclonal, Humanized
  • Anti-Asthmatic Agents